Takeda’s HYQVIA reduces CIDP relapse rates, Phase 3 trial reveals
Takeda Pharmaceutical Company has disclosed successful outcomes from its critical Phase 3 ADVANCE-CIDP 1 trial, focused on evaluating HYQVIA as a maintenance therapy for adults suffering from chronic inflammatory demyelinating polyneuropathy (CIDP). The study found a substantial decrease in relapse rates in patients treated with HYQVIA compared to those given a placebo (9.7% vs 31.4%, […]